Targeted degradation of androgen receptors in androgen-independent prostate cancer cells: an experimental study / 中华男科学杂志
National Journal of Andrology
; (12): 1059-1063, 2009.
Article
in Zh
| WPRIM
| ID: wpr-252867
Responsible library:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To investigate targeted degradation of the androgen receptor (AR) by chimeric molecules (DHT-PROTAC) via the ubiquitin-proteasome pathway in androgen-independent prostate cancer CA-2B cells, and explore the proliferation, secretion and apoptosis of the treated cells.</p><p><b>METHODS</b>C4-2B cells were treated with DHT-PROTAC, and then the expressions of the AR protein and caspase3 in the C4-2B cells were detected by immunohistochemistry and Western blot. The concentration of PSA in the supernatant was examined by ELISA. The cells were counted and their proliferation analyzed by a growth curve. The inhibitory effect on the growth of C4-2B cells was evaluated by MIT assay.</p><p><b>RESULTS</b>Compared with the control group, the DHT-PROTAC-treated group showed an obviously decreased expression of AR proteins with a significant attenuation of the band signals (P < 0.05), a 40% reduction of the AR-positive cells and a 60% decrease of the PSA concentration in the supernatant (P < 0.05). DHT-PROTAC exhibited an inhibitory effect on the C4-2B cells in a time-dependant manner (P < 0.05).</p><p><b>CONCLUSION</b>The chimeric molecule (DHT-PROTAC) can target the degradation of androgen receptors, reduce the secretion of PSA and repress the in vitro growth of C4-2B cells.</p>
Full text:
1
Index:
WPRIM
Main subject:
Pathology
/
Pharmacology
/
Prostatic Neoplasms
/
Receptors, Androgen
/
Prostate-Specific Antigen
/
Apoptosis
/
Cell Line, Tumor
/
Cell Proliferation
/
Drug Therapy
/
Metabolism
Limits:
Humans
/
Male
Language:
Zh
Journal:
National Journal of Andrology
Year:
2009
Type:
Article